Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

UK Myeloma Forum (UKMF) and the British Society for Haematology (BSH)

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


A growing population of long-term survivors of myeloma is now accumulating the 'late effects' not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease. It is thus important to recognise the cumulative burden of the disease and treatment-related toxicity in both the stable and active phases of myeloma, some of which is unlikely to be detected by routine monitoring. We summarise here the evidence for the key late effects in long-term survivors of myeloma, including physical and psychosocial consequences (in Parts 1 and 2 respectively), and recommend the use of late-effects screening protocols in detection and intervention. The early recognition of late effects and effective management strategies should lead to an improvement in the management of myeloma patients, although evidence in this area is currently limited and further research is warranted.

Original languageEnglish
Pages (from-to)888-907
Number of pages20
JournalBritish Journal of Haematology
Issue number6
Early online date20 Jan 2017
Publication statusPublished - Mar 2017


  • Disease Management
  • Humans
  • Multiple Myeloma/diagnosis
  • Outcome Assessment (Health Care)
  • Quality of Life
  • Survivors/psychology
  • Time Factors


Dive into the research topics of 'Guidelines for screening and management of late and long-term consequences of myeloma and its treatment'. Together they form a unique fingerprint.

Cite this